Mar. 5 at 2:16 PM
$ICU Hey AI: Can the selective Cytopheretic device repair the misguided immune response to the pancreas?
The Selective Cytopheretic Device (SCD), also known as QUELimmune, is not currently used to "repair" the autoimmune response in Type 1 Diabetes (T1D). Instead, its primary function is to reprogram activated immune cells to treat life-threatening, hyperinflammatory conditions like Acute Kidney Injury (AKI) and sepsis.
PubMed Central (PMC) (.gov)
PubMed Central (PMC) (.gov)
+1
While it does not specifically target the T1D autoimmune process, its mechanism of action involves "resetting" certain parts of the immune system:
Mechanism of Action: The device uses a biomimetic membrane to selectively bind the most highly activated neutrophils and monocytes (white blood cells) from the blood.
Deactivation: Once bound, these cells are exposed to a low-calcium environment that "reprograms" them from an inflammatory state to a reparative or apoptotic (programmed cell death) state.
Immune Homeostasis: These deactivated cells are released back into the patient’s circulation, signaling the body to lower its overall inflammatory environment and focus on tissue repair.
Nature
Nature
+4
SCD vs. Type 1 Diabetes Treatments
Currently, research for "repairing" the immune response specifically for T1D focuses on other technologies rather than the SCD:
Immunomodulators: Drugs like teplizumab (Tzield) target specific T cells to delay the destruction of insulin-producing beta cells.
Cell Therapy: New trials are exploring "immune-cloaked" or genetically modified islet cells that can evade the immune system entirely without the need for immunosuppressant drugs.
Treg Therapy: Some studies use Regulatory T cells (Tregs) to try and restore peripheral tolerance and stop the autoimmune attack on the pancreas.
Breakthrough T1D
Breakthrough T1D
+4
The SeaStar Medical SCD is currently in a pivotal Phase 3 clinical trial (NEUTRALIZE-AKI) with results expected in 2026. While its success in treating "cytokine storms" suggests potential for other inflammatory diseases, it has not yet been applied to the specific autoimmune "misguided response" seen in Type 1 Diabetes.
BioSpace
BioSpace
+3
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more
The latest from Big Pharma says stay in your own lane SeaStar. We shall see what we shall see.
The first 6 FDA BDDs by 2029/30
The really huge TAM (besides chronic kidney disease/ lifelong dialysis)hyperinflammatory/haywire immune response chronic disease indications will all get Quelimmune tested trials in the next 5 years.
$FMS $BAX will be excellent partners for the necessary funding for the 🌎 🌍 wide sales & distribution and the necessary CMS trials & the worldwide adoption of the Quelimmune SCD.
LOOK OUT BIG PHARMA…..THERE’S A NEW KID IN TOWN.https://youtu.be/S815CEDawOw?si=S-OzUxDATMut-aPJ
